跳至主要内容
临床试验/ACTRN12624000545561
ACTRN12624000545561尚未招募1 期

Safety and efficacy studies of neostigmine administration as a topical ophthalmic solution for diagnosing ocular myasthenia gravis in adults presenting with ptosis

Faculty of Medicine, Chulalongkorn University0 个研究点目标入组 24 人开始时间: 2024年4月30日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients aged 18 years or older who presented with ptosis and were diagnosed with myasthenia gravis by neuro-ophthalmologists or neurologists in the King Chulalongkorn Memorial Hospital

排除标准

  • Patients with generalized myasthenia gravis currently requiring medications, ocular myasthenia gravis currently requiring immunosuppressants, aponeurotic ptosis, mechanical ptosis, traumatic ptosis, other diseases of myogenic or neurogenic ptosis, ophthalmic diseases requiring ophthalmic drops except lubrications, history of eyelid surgery or trauma, patients who had abnormal movement of the eyelids that interfere with the evaluation of the test e.g., eyelid myokymia, facial tics, blepharospasm, and facial spasm, history of neostigmine allergy, or contraindication to neostigmine.

研究者

相似试验